Toxic epidermal necrolysis caused by cetuximab plus minocycline in head and neck cancer

American Journal of Otolaryngology - Head and Neck Medicine and Surgery

Volumn 31, Issue 4, 2010, Pages 288-290

  Lee, Shan Shien ^a   Chu, Pen Yuan ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; MINOCYCLINE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; DRUG WITHDRAWAL; ERYTHEMA; FEVER; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RASH; SKIN DEFECT; SQUAMOUS CELL CARCINOMA; TOXIC EPIDERMAL NECROLYSIS; CARCINOMA, SQUAMOUS CELL; DIFFERENTIAL DIAGNOSIS; DRUG COMBINATION; FOLLOW UP; HEAD AND NECK NEOPLASMS; MIDDLE AGED; PATHOLOGY; STEVENS-JOHNSON SYNDROME;

ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; EPIDERMAL GROWTH FACTOR; EPIDERMAL NECROLYSIS, TOXIC; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; ANTIBODIES, MONOCLONAL, HUMANIZED; STEVENS-JOHNSON SYNDROME;

EID: 77953961311     PISSN: 01960709     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjoto.2009.02.021     Document Type: Article

References (10)

1. Ciardiello F., and Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 358 (2008) 1160-1174
2. Blick S.K., and Scott L.J. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 67 (2007) 2585-2607
3. Scope A., Agero A.L., Dusza S.W., et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 25 (2007) 5390-5396
4. French L.E. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 55 (2006) 9-16
5. Letko E., Papaliodis D.N., Papaliodis G.N., et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 94 (2005) 419-436
6. Lin W.L., Lin W.C., Yang J.Y., et al. Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer. J Clin Oncol 26 (2008) 2779-2780
7. Knowles S.R., and Shear N.H. Recognition and management of severe cutaneous drug reactions. Dermatol Clin 25 (2007) 245-253
8. Roujeau J.C. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 24 (1997) 726-729
9. Roujeau J.C., Kelly J.P., and Naldi L. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333 (1995) 1600-1607
10. Garcia-Doval I., LeCleach L., Bocquet H., et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?. Arch Dermatol 136 (2000) 323-327